Antiparkinsonian activity of adenosine A2A antagonists in experimental models.
Kuwana
Y
Y
Pharmaceutical Research Institute, Kyowa Hakko Kogyo Company, Shizuoka, Japan.
Shiozaki
S
S
Kanda
T
T
Kurokawa
M
M
Koga
K
K
Ochi
M
M
Ikeda
K
K
Kase
H
H
Jackson
M J
MJ
Smith
L A
LA
Pearce
R K
RK
Jenner
P G
PG
D000241:Adenosine / Q000031:analogs & derivatives / Q000494:pharmacology; D000978:Antiparkinson Agents / Q000627:therapeutic use*; D006801:Humans; D009043:Motor Activity / Q000502:physiology; D010300:Parkinson Disease / Q000188:drug therapy*; D010627:Phenethylamines / Q000494:pharmacology; D058915:Purinergic P1 Receptor Antagonists; D018047:Receptors, Purinergic P1 / Q000187:drug effects / Q000502:physiology; D014970:Xanthines / Q000494:pharmacology
D000978:Antiparkinson Agents; D010627:Phenethylamines; D058915:Purinergic P1 Receptor Antagonists; D018047:Receptors, Purinergic P1; D014970:Xanthines; C061282:2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine; C081198:KF 17837; D000241:Adenosine